Aldeyra Therapeutics Inc

자세한 내용은 Aldeyra Therapeutics Inc 회사

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

회사 정보

종목 코드 ALDX

회사 이름Aldeyra Therapeutics Inc

상장일May 02, 2014

CEODr. Todd C. Brady, M.D., Ph.D.

직원 수9

유형Ordinary Share

회계 연도 종료May 02

주소131 Hartwell Avenue

도시LEXINGTON

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호02421

전화17817614904

웹사이트https://www.aldeyra.com/

종목 코드 ALDX

상장일May 02, 2014

CEODr. Todd C. Brady, M.D., Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Todd C. Brady, M.D., Ph.D.

President, Chief Executive Officer, Director

1.42M

+23.16%

Dr. Richard H. Douglas, Ph.D.

Independent Chairman of the Board

125.00K

--

Mr. Martin J. Joyce

Independent Director

23.97K

--

Dr. Gary M. Phillips, M.D.

Independent Director

14.81K

--

Dr. Neal S. Walker

Independent Director

--

Dr. Stephen G. Machatha, Ph.D.

Chief Development Officer

--

Dr. Ben R. Bronstein, M.D.

Independent Director

--

Ms. Nancy B. Miller-Rich

Independent Director

--

Mr. William (Chip) Clark

Independent Director

--

Mr. Michael (Mike) Alfieri

Principal Financial Officer and Principal Accounting Officer

--

이름

이름/직위

직위

주식 보유

변동

Dr. Todd C. Brady, M.D., Ph.D.

President, Chief Executive Officer, Director

1.42M

+23.16%

Dr. Richard H. Douglas, Ph.D.

Independent Chairman of the Board

125.00K

--

Mr. Martin J. Joyce

Independent Director

23.97K

--

Dr. Gary M. Phillips, M.D.

Independent Director

14.81K

--

Dr. Neal S. Walker

Independent Director

--

Dr. Stephen G. Machatha, Ph.D.

Chief Development Officer

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, Aug 16

주주

주주 유형

주주

비율

Knoll Capital Management, LLC

9.14%

Perceptive Advisors LLC

6.76%

BlackRock Institutional Trust Company, N.A.

5.91%

The Vanguard Group, Inc.

5.85%

Ardsley Advisory Partners LP

3.42%

기타

68.92%

주주

비율

Knoll Capital Management, LLC

9.14%

Perceptive Advisors LLC

6.76%

BlackRock Institutional Trust Company, N.A.

5.91%

The Vanguard Group, Inc.

5.85%

Ardsley Advisory Partners LP

3.42%

기타

68.92%

주주 유형

주주

비율

Hedge Fund

19.07%

Investment Advisor

18.01%

Investment Advisor/Hedge Fund

11.10%

Private Equity

6.76%

Individual Investor

3.10%

Research Firm

2.16%

Family Office

0.25%

Pension Fund

0.18%

Bank and Trust

0.09%

기타

39.28%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

295

35.94M

60.00%

-7.70M

2025Q1

315

40.31M

67.37%

-4.94M

2024Q4

306

39.84M

66.72%

-5.42M

2024Q3

295

38.52M

64.82%

-5.60M

2024Q2

290

37.23M

62.65%

-8.21M

2024Q1

294

37.04M

62.88%

-7.70M

2023Q4

296

36.84M

62.63%

-6.52M

2023Q3

298

39.89M

68.07%

-12.41M

2023Q2

305

41.03M

70.05%

-8.66M

2023Q1

311

38.11M

64.83%

-12.64M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Knoll Capital Management, LLC

5.48M

9.14%

--

Mar 31, 2025

Perceptive Advisors LLC

4.88M

8.14%

-4.40M

-47.44%

Apr 03, 2025

BlackRock Institutional Trust Company, N.A.

3.41M

5.7%

-50.91K

-1.47%

Mar 31, 2025

The Vanguard Group, Inc.

3.72M

6.21%

-38.77K

-1.03%

Mar 31, 2025

Ardsley Advisory Partners LP

1.75M

2.92%

+600.00K

+52.17%

Mar 31, 2025

AQR Capital Management, LLC

392.56K

0.66%

+321.99K

+456.32%

Mar 31, 2025

Brady (Todd C)

1.42M

2.38%

+267.69K

+23.16%

Apr 14, 2025

Kingdon Capital Management, L.L.C.

779.00K

1.3%

+779.00K

--

Mar 31, 2025

Geode Capital Management, L.L.C.

1.14M

1.9%

+18.27K

+1.63%

Mar 31, 2025

683 Capital Management LLC

476.00K

0.79%

+186.00K

+64.14%

Mar 31, 2025

5.010USD

Aldeyra Therapeutics Inc

5.010

개요

회사

금융

분석